RAPT Therapeutics Inc
$ 35.84
1.19%
29 Dec - close price
- Market Cap 993,158,000 USD
- Current Price $ 35.84
- High / Low $ 36.25 / 34.78
- Stock P/E N/A
- Book Value 9.02
- EPS -11.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -0.85 %
- 52 Week High 42.39
- 52 Week Low 5.66
About
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to developing innovative oral small molecule therapies for oncology and inflammatory diseases. Utilizing a proprietary drug discovery platform that targets crucial immune regulatory pathways, RAPT is advancing a compelling pipeline designed to meet significant unmet medical needs in the realm of personalized medicine. The company's strategic focus on clinical excellence positions it to deliver transformative therapeutic options, with the potential to substantially improve patient outcomes and redefine standards in immunology.
Analyst Target Price
$65.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-05 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-11 | 2023-05-11 | 2023-03-14 |
| Reported EPS | -0.65 | -0.65 | -0.08 | -1.22 | -0.4738 | -0.71 | -0.79 | -0.8 | -0.82 | -0.66 | -0.76 | -0.64 |
| Estimated EPS | -0.1085 | -0.09 | -0.1361 | -0.3551 | -0.56 | -0.72 | -0.81 | -0.86 | -0.75 | -0.78 | -0.68 | -0.65 |
| Surprise | -0.5415 | -0.56 | 0.0561 | -0.8649 | 0.0862 | 0.01 | 0.02 | 0.06 | -0.07 | 0.12 | -0.08 | 0.01 |
| Surprise Percentage | -499.0783% | -622.2222% | 41.2197% | -243.5652% | 15.3929% | 1.3889% | 2.4691% | 6.9767% | -9.3333% | 15.3846% | -11.7647% | 1.5385% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RAPT
2025-12-25 09:09:38
RAPT Therapeutics (RAPT) has seen an 8% increase after being added to the NASDAQ Biotechnology Index and S&P Biotechnology Select Industry Index, supported by a US$250 million equity raise and progress in its ozureprubart food allergy trial. While these developments reduce near-term financial pressure and sharpen focus on clinical readouts, the company remains unprofitable and its US$65.00 fair value estimate suggests its current price may be inflated. The investment case is still highly dependent on successful clinical execution and future commercialization.
2025-12-25 09:09:15
RAPT Therapeutics (RAPT) has seen an 8.0% increase following its inclusion in the NASDAQ Biotechnology Index and S&P Biotechnology Select Industry Index, along with a US$250 million equity raise and clearance for a Phase 2b food allergy trial. These developments strengthen the company's visibility and cash runway, reducing near-term financing pressures. However, RAPT remains unprofitable with no revenue, making its investment case highly dependent on clinical execution and future commercialization, while a valuation report suggests its current price might be inflated.
2025-12-25 08:09:43
RAPT Therapeutics saw its stock rise by 8.0% following its inclusion in the NASDAQ Biotechnology Index and S&P Biotechnology Select Industry Index, alongside progress in clinical trials and a significant equity raise. The company's investment narrative centers on its lead asset, ozureprubart, with a focus on upcoming Phase 2b food allergy trial readouts. Despite these positive developments, the company remains unprofitable and faces a highly binary investment case heavily dependent on successful clinical execution.
2025-12-23 11:08:52
Rapt Therapeutics (NASDAQ: RAPT) saw its stock rise by 9.8% on Monday, trading at around $37.12 with analyst consensus rating it a "Moderate Buy" and a price target of $50.50. The clinical-stage biotech company is developing RPT193 for atopic dermatitis and allergic asthma, and recently reported a quarterly loss that beat estimates. Institutional investors hold approximately 99% of its stock.
2025-12-21 13:10:33
TD Cowen has initiated coverage on RAPT Therapeutics (RAPT) with a "Buy" rating, primarily due to the potential of their lead candidate, ozureprubart. Analysts view this candidate as superior to Xolair for food allergy and chronic spontaneous urticaria, citing promising Phase 2 data and anticipated Phase 3 launch in late 2026. The company has also made significant clinical and operational progress, including FDA clearance for a Phase 2b food allergy trial and a $250 million equity offering extending its cash runway.
2025-12-20 10:09:51
Rapt Therapeutics (NASDAQ:RAPT) has received a "Moderate Buy" consensus recommendation from thirteen analysts, with an average one-year price target of $50.50. The company, which is developing tissue-selective immunology drugs like RPT193 for atopic dermatitis and allergic asthma, has also seen significant institutional interest and reported better-than-expected Q3 EPS. Hedge funds hold about 99.09% of the shares as the stock trades near $33.81.
